LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

Search

Corvus Pharmaceuticals Inc

Închisă

3.77 -0.79

Rezumat

Modificarea prețului

24h

Curent

Minim

3.77

Maxim

3.82

Indicatori cheie

By Trading Economics

Venit

27M

15M

EPS

-0.138

Angajați

31

EBITDA

-1.8M

-9.9M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+243.92% upside

Dividende

By Dow Jones

Următoarele câștiguri

5 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-6.6M

270M

Deschiderea anterioară

4.56

Închiderea anterioară

3.77

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

Corvus Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

31 mai 2025, 10:30 UTC

Top știri

Pension Funds Won't Save the Bond Market -- Heard on the Street -- WSJ

31 mai 2025, 06:30 UTC

Câștiguri

5 Things We've Learned From Retail Earnings -- Barrons.com

31 mai 2025, 04:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

30 mai 2025, 23:51 UTC

Achiziții, Fuziuni, Preluări

Trump Raises Steel Tariffs, Saying U.S. Steel Will Remain U.S.-Controlled -- Update

30 mai 2025, 21:30 UTC

Top știri

Stocks Shrug Off Trade War to Post Best Month Since 2023 -- WSJ

30 mai 2025, 21:15 UTC

Top știri

The Score: E.l.f. Beauty, Tesla, Nvidia, and More Stocks That Defined the Week -- WSJ

30 mai 2025, 20:50 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Health Care Roundup: Market Talk

30 mai 2025, 20:44 UTC

Achiziții, Fuziuni, Preluări

Bill Ackman Is Killing It. A New ETF Will Track His Investments. -- Barrons.com

30 mai 2025, 20:24 UTC

Top știri

Major U.S. Stock Indexes Finish About Flat; U.S.-China Trade Friction Renews -- WSJ

30 mai 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

30 mai 2025, 19:44 UTC

Market Talk

Gold Breaks 4-Month Winning Streak -- Market Talk

30 mai 2025, 19:38 UTC

Market Talk

Companies Delay or Cancel $14B In Clean-Energy Investments -- Market Talk

30 mai 2025, 19:29 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

NRG Energy and UnitedHealth Are the S&P 500's Best and Worst for May. Here's Why. -- Barrons.com

30 mai 2025, 19:14 UTC

Market Talk

Oil Settles Lower Ahead of OPEC+ Output Decision -- Market Talk

30 mai 2025, 19:05 UTC

Market Talk

U.S. Natural Gas Futures Fall Awaiting Hotter Weather -- Market Talk

30 mai 2025, 18:51 UTC

Market Talk

Canada's Retaliatory Tariffs Help Fuel Sizable Rise in Tax Revenue -- Market Talk

30 mai 2025, 18:37 UTC

Market Talk
Câștiguri

Costco Well Positioned for Sustainable Growth, UBS Says -- Market Talk

30 mai 2025, 18:04 UTC

Top știri

S&P 500 Falls After More Trump-China Friction -- WSJ

30 mai 2025, 17:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30 mai 2025, 17:47 UTC

Market Talk

Time for BoC Gov. Macklem to Cut Rates, Desjardins Says -- Market Talk

30 mai 2025, 17:40 UTC

Achiziții, Fuziuni, Preluări

Trump Is Praising His U.S. Steel Deal. No One Is Sure What It Means -- WSJ

30 mai 2025, 17:38 UTC

Market Talk

U.S: Oil Rig Count Falls for Fifth Straight Week -- Market Talk

30 mai 2025, 17:31 UTC

Market Talk

Costco Well Positioned to Gain Share Amid Tariffs, Baird Says -- Market Talk

30 mai 2025, 17:14 UTC

Top știri

American Consumers Are Still Gloomy on the Economy -- 3rd Update

30 mai 2025, 16:31 UTC

Câștiguri

Ulta Beauty Stock Is Rising. Earnings Strength Was More Than Cosmetic. -- Barrons.com

30 mai 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

30 mai 2025, 16:20 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Health Care Roundup: Market Talk

30 mai 2025, 16:16 UTC

Top știri

S&P 500 Falls After Trump Hits Out at China -- WSJ

30 mai 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

30 mai 2025, 16:14 UTC

Top știri

HSBC Retreats From Banking Smaller U.S. Businesses -- WSJ

Comparație

Modificare preț

Corvus Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

243.92% sus

Prognoză pe 12 luni

Medie 13 USD  243.92%

Maxim 17 USD

Minim 11 USD

În baza a 3 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCorvus Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

3 ratings

3

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

3.165 / 3.5827Suport & Rezistență

Termen scurt

Strong Bearish Evidence

Termen mediu

Bearish Evidence

Termen lung

Weak Bearish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.